Mirikizumab study for ulcerative colitis patients
Part of Digestive system clinical trials.
This study follows people with ulcerative colitis who are starting or have just started mirikizumab treatment. It aims to understand how well the drug works in real-world settings and how patients do over the next 12 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with moderate to severe ulcerative colitis (UC).
- You have started mirikizumab within the last 2 weeks or plan to start it within the next 2 weeks as part of your regular care.
- Your doctor expects to follow you for the next 12 months.
- You can provide consent and speak English.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
This study tests two drugs together (LY4268989 and mirikizumab) in people with moderate to severe ulcerative colitis. It's for those whose current treatments didn't work well enough.
This study tests two experimental drugs, Eltrekibart and Mirikizumab, for adults with moderate to severe ulcerative colitis who have not responded well to other treatments. The goal is to see if these drugs can help control the disease.
This study tests whether adding mirikizumab to the weight-loss drug tirzepatide helps people with moderate-to-severe ulcerative colitis who also have obesity or overweight. It aims to see if the combination reduces bowel inflammation and helps with weight management.
This study tests risankizumab (a medication that targets inflammation) in young people with ulcerative colitis who haven't improved enough on other treatments. It aims to see if risankizumab can help control symptoms and reduce bowel inflammation.
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.